Latest Insider Transactions at Dyne Therapeutics, Inc. (DYN)
This section provides a real-time view of insider transactions for Dyne Therapeutics, Inc. (DYN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Dyne Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Dyne Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2022
|
Jason P Rhodes |
BUY
Open market or private purchase
|
Indirect |
934,581
+50.0%
|
$9,345,810
$10.7 P/Share
|
|
Dec 12
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
680
-0.75%
|
$6,800
$10.87 P/Share
|
|
Dec 12
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
3,322
-1.0%
|
$33,220
$10.87 P/Share
|
|
Dec 12
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
628
-0.62%
|
$6,280
$10.87 P/Share
|
|
Dec 12
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
751
-0.67%
|
$7,510
$10.87 P/Share
|
|
Dec 12
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
472
-0.48%
|
$4,720
$10.87 P/Share
|
|
Dec 12
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
312
-0.55%
|
$3,120
$10.87 P/Share
|
|
Dec 09
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+30.58%
|
-
|
|
Dec 09
2022
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
144,000
+30.18%
|
-
|
|
Dec 09
2022
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+26.33%
|
-
|
|
Dec 09
2022
|
Susanna Gatti High Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+28.06%
|
-
|
|
Dec 09
2022
|
Jonathan Mc Neill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+28.94%
|
-
|
|
Dec 09
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
31,000
+35.43%
|
-
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
SELL
Bona fide gift
|
Direct |
15,500
-3.83%
|
-
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
195,800
-48.9%
|
$2,349,600
$12.46 P/Share
|
|
Oct 10
2022
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
195,800
+32.84%
|
$195,800
$1.03 P/Share
|
|
Oct 07
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
14,200
-6.49%
|
$184,600
$13.37 P/Share
|
|
Oct 07
2022
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
14,200
+6.09%
|
$14,200
$1.03 P/Share
|
|
Sep 20
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
840
-3.19%
|
$10,920
$13.7 P/Share
|
|
Sep 20
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,246
-2.1%
|
$16,198
$13.7 P/Share
|
|
Sep 20
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,629
-3.68%
|
$34,177
$13.7 P/Share
|
|
Sep 20
2022
|
Joshua T Brumm CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,836
-5.47%
|
$153,868
$13.7 P/Share
|
|
Sep 20
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,413
-2.7%
|
$18,369
$13.7 P/Share
|
|
Sep 15
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
712
-1.34%
|
$9,968
$14.05 P/Share
|
|
Sep 15
2022
|
Joshua T Brumm CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,480
-1.58%
|
$48,720
$14.05 P/Share
|
|
Sep 15
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
786
-1.09%
|
$11,004
$14.05 P/Share
|
|
Sep 15
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
494
-0.82%
|
$6,916
$14.05 P/Share
|
|
Sep 15
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
658
-1.01%
|
$9,212
$14.05 P/Share
|
|
Sep 15
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
326
-1.22%
|
$4,564
$14.05 P/Share
|
|
Jul 06
2022
|
Joshua T Brumm CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,963
-4.75%
|
$87,704
$8.24 P/Share
|
|
Jul 05
2022
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
24,118
+9.46%
|
-
|
|
Jun 14
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
726
-1.35%
|
$2,904
$4.95 P/Share
|
|
Jun 14
2022
|
Joshua T Brumm CEO & President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,540
-1.68%
|
$14,160
$4.95 P/Share
|
|
Jun 14
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
668
-1.01%
|
$2,672
$4.95 P/Share
|
|
Jun 14
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
802
-1.1%
|
$3,208
$4.95 P/Share
|
|
Jun 14
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
504
-0.83%
|
$2,016
$4.95 P/Share
|
|
Jun 14
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
333
-1.23%
|
$1,332
$4.95 P/Share
|
|
Mar 11
2022
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
693
-1.27%
|
$5,544
$8.73 P/Share
|
|
Mar 11
2022
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
3,384
-1.58%
|
$27,072
$8.73 P/Share
|
|
Mar 11
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
640
-0.96%
|
$5,120
$8.73 P/Share
|
|
Mar 11
2022
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
765
-1.04%
|
$6,120
$8.73 P/Share
|
|
Mar 11
2022
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
481
-0.79%
|
$3,848
$8.73 P/Share
|
|
Mar 11
2022
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
308
-1.13%
|
$2,464
$8.73 P/Share
|
|
Mar 02
2022
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,617
-7.77%
|
$44,936
$8.56 P/Share
|
|
Dec 10
2021
|
Oxana Beskrovnaya Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,524
+40.18%
|
-
|
|
Dec 10
2021
|
Joshua T Brumm CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
118,190
+35.61%
|
-
|
|
Dec 10
2021
|
Wildon Farwell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,307
+23.58%
|
-
|
|
Dec 10
2021
|
Susanna Gatti High Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,315
+35.34%
|
-
|
|
Dec 10
2021
|
Jonathan Mc Neill Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,311
+29.34%
|
-
|
|
Dec 10
2021
|
Richard William Scalzo SVP, Head of Finance & Admin. |
BUY
Grant, award, or other acquisition
|
Direct |
16,696
+37.95%
|
-
|